title: [Gefitinib for advanced bronchioloalveolar carcinoma].
abstract: We described 3 cases of advanced bronchioloalveolar carcinoma (BAC), in whom once-daily treatment with 250 mg Gefitinib (Iressa) demonstrated remarkable antitumor effects. Gefitinib may produce dramatic clinical responses when administered to patients with poor performance status who had received heavy platinum/docetaxel-based prior chemotherapy.
authors.affiliation: Department of Respiratory Disease, PUMC Hospital, CAMS and PUMC, Beijing 100730, China.
authors.forename: Xiao-tong
authors.initials: XT
authors.lastname: Zhang
authors.forename: Shu-lan
authors.initials: SL
authors.lastname: Wang
authors.forename: Long-yun
authors.initials: LY
authors.lastname: Li
mesh_terms: D002282:Adenocarcinoma, Bronchiolo-Alveolar / Q000188:drug therapy*; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008875:Middle Aged; D011799:Quinazolines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D066246:ErbB Receptors; D000077156:Gefitinib